



# Conclusions

Dr. Byoung-Gie Kim



# The 3 Es of ICI in endometrial cancer

Emergence, evolution, and expansion



# Conclusions

- The treatment landscape for front-line EC has dramatically changed following the recent positive results from clinical trials, and subsequent regulatory approvals have just begun
  - The first approval for an immunotherapy (dostarlimab) in combination with chemotherapy for patients with advanced or first recurrent dMMR/MSI-H EC took place on July 31, 2023 (FDA)
    - MHRA approval (October 2, 2023)
    - Positive CHMP opinion (October 12, 2023)
  - Treatment with immunotherapy earlier in the treatment paradigm has the potential to alter the outcomes and journey of patients with EC
- As immunotherapy moves earlier in the treatment pathway, ongoing questions include:
  - How to treat patients who experience relapse post-chemotherapy + immunotherapy?
  - How do we further validate the prognostic value of molecular subgroups for identifying those patients who will benefit the most?
  - What novel combinations should be explored with IO?

**Please take time to complete the evaluation by scanning the QR code**

Thank you for your valuable feedback.

The exclusive purpose of this evaluation is to enhance the quality of our events.

All feedback will remain confidential.



# Thank you!

## Questions & Answers

